Edition:
United States

Agios Pharmaceuticals Inc (AGIO.OQ)

AGIO.OQ on NASDAQ Stock Exchange Global Select Market

89.36USD
4:00pm EDT
Change (% chg)

$0.74 (+0.84%)
Prev Close
$88.62
Open
$88.36
Day's High
$89.77
Day's Low
$88.36
Volume
69,789
Avg. Vol
194,565
52-wk High
$92.09
52-wk Low
$45.97

Chart for

About

Agios Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company's cancer product candidates are... (more)

Overall

Beta: 1.99
Market Cap(Mil.): $5,105.01
Shares Outstanding(Mil.): 57.61
Dividend: --
Yield (%): --

Financials

  AGIO.OQ Industry Sector
P/E (TTM): -- 243.17 32.94
EPS (TTM): -6.81 -- --
ROI: -47.12 -7.30 12.79
ROE: -57.86 -10.05 14.67

BRIEF-Agios Qtrly Loss Per Share $1.63

* AGIOS PROVIDES BUSINESS UPDATE ON DISCOVERY RESEARCH STRATEGY AND PIPELINE, PROGRESS ON CLINICAL PROGRAMS, COMMERCIAL LAUNCH PREPARATIONS AND REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AT INVESTOR DAY

May 04 2018

BRIEF-Agios Says First Patient Dosed In Lymphoma Study

* AGIOS ANNOUNCES FIRST PATIENT DOSED WITH MAT2A INHIBITOR AG-270 IN PHASE 1 STUDY IN PATIENTS WITH ADVANCED SOLID TUMORS OR LYMPHOMA WITH AN MTAP DELETION Source text for Eikon: Further company coverage:

Mar 19 2018

BRIEF-Agios Reports Qtrly Loss Per Share $1.81

* AGIOS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

Feb 14 2018

Celgene to buy Juno for $9 billion to boost cancer pipeline

Celgene Corp will pay $9 billion in cash to buy experimental cancer drugmaker Juno Therapeutics Inc, bulking up its developmental pipeline as it works to reduce reliance on its own cancer treatment Revlimid. | Video

Jan 22 2018

UPDATE 3-Celgene to buy Juno for $9 bln to boost cancer pipeline

* Juno's CAR-T drug could rake in $3 bln worldwide in peak sales (Adds background and analyst quote, updates share price)

Jan 22 2018

Agios sizes up funding needs

Jan 19 (IFR) - Agios Pharmaceuticals pivoted from industry conferences to the capital markets, securing US$425m in a follow-on stock sale that meets its funding needs for the year.

Jan 19 2018

BRIEF-Agios prices offering of 7.09 mln shares at $67 per share

* AGIOS ANNOUNCES PRICING OF $475 MILLION PUBLIC OFFERING OF COMMON STOCK

Jan 18 2018

BRIEF-Agios Announces Proposed Offering Of Common Stock

* SAYS IT IS OFFERING TO SELL UP TO $400 MILLION OF ITS COMMON STOCK IN A PUBLIC OFFERING

Jan 17 2018

BRIEF-Agios Outlines Key 2018 Priorities Expanding Clinical And Research Programs To Drive Long Term Value

* AGIOS OUTLINES KEY 2018 PRIORITIES EXPANDING CLINICAL AND RESEARCH PROGRAMS TO DRIVE LONG TERM VALUE

Jan 08 2018

BRIEF-Agios Submits New Drug Application To The FDA For Ivosidenib

* AGIOS SUBMITS NEW DRUG APPLICATION TO THE FDA FOR IVOSIDENIB FOR THE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY AML AND AN IDH1 MUTATION

Dec 26 2017

Competitors

  Price Chg
Pfizer Inc. (PFE.N) $35.68 -0.21
Novartis AG (NOVN.S) CHF75.56 -0.10
Roche Holding Ltd. (ROG.S) CHF217.60 -1.40
Roche Holding Ltd. (RO.S) CHF221.00 -2.40
Sanofi SA (SASY.PA) €65.78 0.00
AstraZeneca plc (AZN.L) 5,478.00 +50.00
GlaxoSmithKline plc (GSK.L) 1,500.00 +5.80
Eli Lilly And Co (LLY.N) $82.77 +0.06
Shire PLC (SHP.L) 4,133.50 +30.50
Shire PLC (3159084.L) -- --

Earnings vs. Estimates